Show simple item record

dc.contributor.authorMansoor, Was
dc.contributor.authorArkenau, H. T.
dc.contributor.authorAlsina, M.
dc.contributor.authorShitara, K.
dc.contributor.authorThuss-Patience, P.
dc.contributor.authorCuffe, S.
dc.contributor.authorDvorkin, M.
dc.contributor.authorPark, D.
dc.contributor.authorAndo, T.
dc.contributor.authorVan Den Eynde, M.
dc.contributor.authorBeretta, G. D.
dc.contributor.authorZaniboni, A.
dc.contributor.authorDoi, T.
dc.contributor.authorTabernero, J.
dc.contributor.authorIlson, D. H.
dc.contributor.authorMakris, L.
dc.contributor.authorBenhadji, K. A.
dc.contributor.authorVan Cutsem, E.
dc.date.accessioned2021-04-20T08:08:21Z
dc.date.available2021-04-20T08:08:21Z
dc.date.issued2021en
dc.identifier.citationMansoor W, Arkenau HT, Alsina M, Shitara K, Thuss-Patience P, Cuffe S, et al. Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. Gastric Cancer. 2021.en
dc.identifier.pmid33713215en
dc.identifier.doi10.1007/s10120-021-01156-xen
dc.identifier.urihttp://hdl.handle.net/10541/623937
dc.description.abstractBackground: Patients with advanced gastroesophageal junction cancer (GEJC) have poor survival outcomes, and GEJC-specific data from trials evaluating agents in gastric cancers (GCs) as a whole are lacking. Trifluridine/tipiracil (FTD/TPI) was approved for previously treated metastatic GC or GEJC (mGC/mGEJC) based on results of the phase 3 TAGS trial. Subgroup analyses by primary tumor type (GC or GEJC) in TAGS are reported here. Methods: Pa tients with mGC/mGEJC treated with ≥ 2 prior chemotherapy regimens were randomized (2:1) to receive FTD/TPI or placebo, plus best supportive care. A pre-planned sub-analysis was performed to evaluate efficacy and safety outcomes by primary tumor type (GEJC or GC). Results: Of 507 randomized patients, 145 (29%) had GEJC and 360 (71%) had GC as the primary disease site. Baseline characteristics were generally similar between the GEJC and GC subgroups, except that more patients in the GEJC subgroup had received ≥ 3 prior regimens (72 vs. 59% in the GC subgroup). Survival benefit with FTD/TPI was observed in both subgroups. The overall survival hazard ratio for FTD/TPI vs placebo was 0.75 (95% CI 0.50-1.11) and 0.67 (95% CI 0.52-0.87) in the GEJC and GC subgroups, respectively. Grade ≥ 3 adverse events of any cause were reported in 75 (77%) and 192 (81%) FTD/TPI-treated patients in the GEJC and GC subgroups, respectively. No new safety concerns were noted with FTD/TPI. Conclusion: As in patients with GC, FTD/TPI showed an efficacy benefit in patients with GEJC in the TAGS trial, along with demonstrating a manageable safety profile.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s10120-021-01156-xen
dc.titleTrifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS studyen
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalGastric Canceren
dc.description.noteen]
refterms.dateFOA2021-04-26T08:16:00Z


Files in this item

Thumbnail
Name:
33713215.pdf
Size:
1.609Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record